Heartfelt invests in Cori Clinical
Funding Provisional 76% confidence first seen
Cori Clinical raised a $4 million seed round led by Breega with participation including Heartfelt. The company said the funds will be used to expand delivery capacity, grow its team, and deepen its regulatory and clinical intelligence, aimed at improving clinical trial protocol design and reducing start-up delays and costs. This matters as Heartfelt’s investment signals support for AI tooling that consolidates prior trial knowledge with regulatory and registry information to streamline trial set-up.
The deal
Cori Clinical $4M Seed · announced 7 Oct 2026
Investors Breega Enzo Heartfelt Together Ventures Bynd
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Cori Clinical raised a $4 million seed round led by Breega, with participation from Heartfelt and other investors. Cori said it will use the funding to expand delivery capacity, hire staff, and deepen its regulatory and clinical intelligence for its AI platform that helps generate clinical trial protocols and plans.
- Why it matters
- For healthcare and life sciences leaders, Heartfelt’s participation adds investor support behind AI tools aimed at reducing clinical trial start-up friction by combining prior trial knowledge with regulatory and registry data. If adopted effectively, this type of tooling could affect trial design workflows, operating timelines, and early-stage development costs, but the current support in coverage comes from company-stated estimates rather than independent validation.
- Evidence
- The event is supported by a single Tech.eu report describing the $4 million seed round, Breega as lead investor, Heartfelt as a participant, and Cori’s stated intended uses of proceeds. The same report attributes performance claims such as 33% lower trial set-up costs and 82% avoidable protocol errors to the company, with no independent corroboration in the provided coverage.
- What remains uncertain
- It is unclear how much Heartfelt invested, what strategic role it will play beyond capital, and whether its participation reflects a broader investment thesis or a one-off bet. The operational impact of Cori’s platform is also uncertain because the reported cost and error-reduction figures are company estimates and internal review results, not externally validated outcomes.
- Monitor next
- Watch for customer deployments or independently validated case studies showing whether Cori’s platform measurably reduces protocol errors, start-up delays, or trial set-up costs in production use.
Analytical support, not advice — assumptions and open questions stated above.